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Introduction: Computed tomography and magnetic resonance imaging are able to demonstrate and to diagnose
hepatic focal nodular hyperplasia when a typical pattern of a well-circumscribed lesion with a central scar is present.
Our aim is to propose the split-bolus multidetector-row computed tomography technique as an alternative to the
conventional triphasic technique in the detection and characterization of focal nodular hyperplasia to reduce the
radiation dose to the patient.
To the best of our knowledge, this is the first report regarding the application of the split-bolus computed tomography
technique in the evaluation of hepatic focal nodular hyperplasia.
Case presentation: We describe a case of focal nodular hyperplasia of the liver in a 53-year-old Caucasian woman
(weight 75Kg) with a colorectal adenocarcinoma histologically confirmed. An innovative split-bolus multidetector-row
computed tomography technique was used that, by splitting intravenous contrast material in two boli, combined two
phases (hepatic arterial phase and portal venous phase) in a single pass; a delayed (5 minutes) phase was obtained to
compare the findings with that of triphasic multidetector-row computed tomography.
Conclusions: Split-bolus multidetector-row computed tomography was able to show the same appearance of the
lesion as the triphasic multidetector-row computed tomography technique.
This is the first case demonstrating the effectiveness of the split-bolus multidetector-row computed tomography
technique in the detection and characterization of focal nodular hyperplasia with a significant reduction in radiation
dose to the patient with respect to triphasic multidetector-row computed tomography technique.
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Triphasic techniqueIntroduction
Focal nodular hyperplasia (FNH) is the second most com-
mon benign tumor of the liver after hemangioma; its
etiology is still unclear [1]. In most patients, the clinical
course is silent and FNH is often discovered incidentally
during radiologic imaging performed for other reasons.
The lesion typically is well circumscribed with a central
scar. Although FNH usually has no clinical significance,
recognition of the radiologic characteristics of hepatic* Correspondence: michelescialpi@libero.it
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unless otherwise stated.FNH is important to avoid unnecessary surgery, biopsy,
and follow-up imaging [2,3].
Triphasic helical computed tomography (CT) scans –
hepatic arterial phase (HAP), portal venous phase (PVP)
and delayed phase (DP) – represent an accurate technique
in the characterization of typical FNH [4].
Split-bolus protocol is an innovative technique that, by
splitting intravenous contrast medium into two boli and
combining phase images in a single scan, is used in sev-
eral CT applications [5,6].
To the best of our knowledge the application of the
split-bolus CT technique in the characterization of FNH
of the liver has not been reported.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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split-bolus multidetector-row CT (MDCT) technique in
the characterization of FNH of the liver.
Case presentation
A 53-year-old Caucasian woman with a colorectal adeno-
carcinoma, histologically confirmed, underwent pre-
operative triphasic MDCT of her chest-abdomen-pelvis,
magnetic resonance imaging (MRI) and follow-up
split-bolus MDCT. Triphasic and split-bolus MDCT
were performed by Philips Brilliance 64-detector row
scanner (Philips Healthcare, Best, The Netherlands).
The triphasic MDCT protocol consisted of unenhanced
images and a HAP (started 40 seconds after the injection
of the contrast medium or 20 seconds after threshold of
150 Hounsfield units, HU, in her thoracic-abdominal aorta
by using a bolus-tracking technique) of her upper abdo-
men, a PVP (started 40 seconds after the end of HAP ac-
quisition) of her chest-abdomen-pelvis and a DP (after 5
minutes to the start of injection) of her upper abdomen. A
bolus administration of intravenous contrast material
(iopamidole, Iopamiro®; Bracco, Milan, Italy; 1.5mL per kg
body weight, containing 370mg iodine/mL) was injected
at 4.0mL/second via an injector at a rate of 4.0mL/second
from an antecubital vein using an 18 gauge needle.
Triphasic MDCT demonstrated a lesion (5.5cm in max-
imum diameter) in the right lobe of her liver with diffuse
immediate homogeneous hyperdense enhancement on
HAP, washout of contrast medium becoming isodense to
her liver on PVP and DP at 5 minutes. Scar was hypodense
to the liver on unenhanced phase, showing a progressive
enhancement throughout the three phases with maximum
peak on DP (Figure 1). A diagnosis of FNH was suggested.
Her radiation dose – the effective dose (sievert, Sv)
was calculated using the following equation: effective
dose = k × dose-length-product; k = 0.015 (conversionFigure 1 Triphasic 64-detector row computed tomography findings o
contrast-enhanced computed tomography scan shows intense homogeneou
computed tomography scan during the portal venous phase shows lesion ex
compared with surrounding liver (b); delayed phase contrast-enhanced co
enhancement of central scar (c).coefficient) [7] – obtained during triphasic MDCT was
38.87mSv. The total number of the images was 878.
MRI with liver-specific hepatobiliary contrast agent
gadoxetic was done, showing a hypervascular soft tissue
lesion consistent with a diagnosis of FNH. Laboratory data
were all within the normal range. Liver and other specific
tumor markers (alpha-fetoprotein, CA 19–9, carcinoem-
bryonic antigen) turned out negative. At follow-up after
12 months from the initial triphasic MDCT, a split-bolus
MDCT protocol was used.
The split-bolus MDCT protocol consisted of unenhanced
low-dose of her upper abdomen; a single acquisition of the
chest-abdomen-pelvis after intravenous injection of 150mL
of contrast medium (370mgI/mL, iopamidole, Iopamiro®;
Bracco, Milan, Italy), split by an automatic power injector
(Stellant, CT; Medrad, Indianola, Pa, USA) into two
boluses (Figure 2).
Using the scout film, a scan range from her pulmonary
apex to her pubic symphysis was determined. Then a cir-
cular region of interest of the bolus-tracking technique
(raising the threshold value at 500 HU) was placed in the
descending aorta. At the start of the second bolus contrast
medium injection, the scan started cranio-caudally after a
delay of 6 seconds from the arrival of the contrast medium
into her aorta. The inherent 6-second delay in the bolus-
tracking technique is necessary to move the scan table to
the start of the scan, give breath-hold instructions to the
patient, and tune the gantry parameters.
A single contrast-enhanced acquisition of the chest-
abdomen-pelvis was acquired, resulting in a simultaneous
contrast enhancement of her arterial and venous system.
Split-bolus MDCT showed the typical hyperdense
enhancement of the lesion with hypodense central scar
at the combined phase images (HAP/PVP during hep-
atic enhancement) and isodensity with hyperdensity of
central scar at DP (5 minutes; Figure 3).f focal nodular hyperplasia in a 53-year-old woman. Arterial phase
s enhancement with hypodense focal central scar (a); contrast-enhanced
hibiting rapid contrast material washout being slightly hypo-attenuated
mputed tomography scan shows lesion as isodense and persistent
Figure 2 Schematic view of split-bolus 64-detector row computed tomography scanning of the chest and abdomen of a 53-year-old
Caucasian woman (weight 75kg) with a colorectal adenocarcinoma and incidental liver focal nodular hyperplasia. First bolus at the start
of bolus injection, or time zero: 90mL (1.2mL/kg) of contrast medium at 2.0mL/second, followed by 20mL of saline solution at the same flow rate,
is injected to obtain adequate hepatic enhancement during the portal venous phase. Second bolus: 60mL of contrast medium at 3.5mL/second
followed by 20mL of saline solution at the same flow rate to obtain hepatic arterial phase. A single contrast-enhanced acquisition from the pulmonary
apex to the pubic symphysis was acquired. A circular region of interest of the bolus-tracking technique was placed in the descending aorta. At the start
of the second bolus contrast medium injection, the scan started cranio-caudally after a delay of 6 seconds from the arrival of the contrast medium into
the aorta. Abbreviations: sec, second(s); Tarr, arrival time of the contrast medium into the aorta.
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was 22.78mSv. The total number of the images was 637.
Split-bolus MDCT demonstrated no differences in quan-
titative analysis in HU on liver parenchyma, portal vein
and aorta with respect to triphasic MDCT technique
(Figure 4).
For triphasic and split-bolus MDCT protocol, the fol-
lowing acquisition parameters were used: slice thickness
2.5mm; gantry rotation speed 0.75 seconds; reconstruc-
tion index 1.25; pitch 0.935:1; 120 peak kilovoltage and
automatic tube current (mA) was set on the basis of the
patient’s weight using z-axis modulation. MDCT examina-
tions were completed with sagittal, coronal and curved
multiplanar reconstructions.
Images were transferred to an external workstation
(Advantage Workstation 4.2, GE Healthcare, Milwaukee,
USA and Magic View, Philips Medical Systems, Best,Figure 3 Single-pass 64-detector row computed tomography findings
(hepatic arterial phase/portal venous phase during hepatic enhancement) s
central scar (a); on delayed phase (b) the lesion appears substantially isodeThe Netherlands) and stored in a picture archiving and
communication system (PACS, Agfa Healthcare, Impax).
Discussion
Focal nodular hyperplasia (FNH) of the liver remains a
largely asymptomatic disease that patients often only dis-
cover after vague abdominal symptoms or from imaging
for another medical concern [8].
Accurate diagnosis is important in FNH as it dictates
the course of treatment. In most cases, FNH usually pre-
sents with classic CT and MRI features, helping to narrow
the differential diagnosis and negating the need for biopsy
or further studies [9-11].
In general, FNH of the liver appears as a solitary nod-
ule smaller than 5cm in diameter, usually lobulated and
well circumscribed, although unencapsulated [12,13]. On
cut section the pathognomonic feature is the presence ofof focal nodular hyperplasia in 53-year-old woman. Mixed phase
hows intense homogeneous enhancement with hypodense focal
nse to liver parenchyma with persistent enhancement of central scar.
Figure 4 Circular region of interest measurements of portal vein and liver parenchyma performed during portal venous phase (a) of
the triphasic computed tomography and during combined phase (b) of the single-pass split-bolus computed tomography. Mixed phase
(hepatic arterial phase/portal venous phase during hepatic enhancement) of the split-bolus multidetector-row computed tomography shows a
higher attenuation of the portal vein and liver parenchyma with respect to that of the portal venous phase of the triphasic multidetector-row
computed tomography protocol. Abbreviations: Avg, average; Dev, standard deviation; HU, Hounsfield unit.
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with broad strands radiating from it to the periphery in a
stellate configuration. The central scar contains thick-
walled vessels that provide excellent arterial blood supply
to the lesion and, therefore, these tumors are usually
homogeneous (with internal necrosis and hemorrhage be-
ing extremely rare) [12,13]. On microscopic examination,
all the components of the normal liver lobule are present.
The cellular morphology and relationship between hepa-
tocytes and bile ducts are essentially those of normal liver,
both by light and by electron microscopic criteria.
Triphasic CT has gained acceptance as the preferred
technique for the evaluation of a wide range of liver lesions,
like FNH, as demonstrated in the literature [3,8]. Most
FNHs are isodense or slightly hypodense to the liver on
unenhanced CT [13]; when isodense to the liver, the le-
sions may be detectable only because of mass effect [3].
Typical FNH, during the HAP shows an immediate
and intense enhancement (96%) relating to the hypervas-
cularity of the tumor, with rapid washout of contrast
medium becoming isodense to the liver during the peak
of PVP and delayed images [14]. Scars is hypodense to
the liver on unenhanced and early contrast-enhanced
images, showing a progressive enhancement throughout
the HAP and PVP with maximum peak in DP caused by
the presence of abundant myxomatous stroma [14].
An enhancing vessel may be seen in the scar on arterial
phase imaging, representing the intratumoral portion of
the feeding artery. On occasion, contrast-enhanced images
reveal hypoenhancing radiating fibrous septa. These septa
usually divide the tumor into sections because they radiate
from the central scar toward the periphery.
On triphasic helical CT examination hepatomas, hyper-
vascular metastases, FNH and adenomas may all appear
similar. Gadoxetate disodium-enhanced MRI when the
standard series are combined with the hepatobiliary phase
shows high accuracy for diagnosis of FNH and to differenti-
ate it from adenoma in lesions larger than 2cm [15,16].To the best of our knowledge there are no reports
concerning the use of the split-bolus MDCT technique
in the detection and characterization of FNH.
Spli-bolus technique is an innovative CT imaging in-
vestigation that combines the HAP and the PVP hepatic
enhancement in a single acquisition allowing the identi-
fication of hypodense, hyperdense and mixed lesions.
Similar to triphasic MDCT, a DP of the upper abdomen
further helps in the characterization of the lesion [17].
Split-bolus technique consists in splitting intravenous
contrast medium into two boli, performing MDCT ac-
quisition in a single pass. The rationale is similar to that
of a CT urography protocol [18], with the same goal to
standardize a split-bolus MDCT protocol to ensure diag-
nostic efficacy and reduce radiation dose [19,20].
To understand the split-bolus MDCT protocol and
MDCT appearance of the reported FNH, it is essential
to know the peak enhancement time of main portal vein
and liver related to patient weight, determined by the first
bolus of contrast medium.
Erturk et al. [21] reported relationships between
patient weight, peak enhancement time of main portal
vein and liver. In patients with weight ranging from 60 to
70kg, at 40 and 45 seconds of contrast medium injection
duration time, an optimal enhancement peak of the main
portal vein (212.4 ±20.4 HU and 206.5 ±19.2 HU) and of
the liver (59.8 ±9.6 HU and 58.9 ±7.8 HU) respectively
was obtained.
In our split-bolus MDCT protocol, using for first bolus
90mL of contrast medium (1.2mL/kg of 370mgI/mL) with
a fixed flow rate of 2mL/second and duration injection
time of 45 seconds in a patient weighing 75kg, an optimal
attenuation in HU of the aorta, the liver parenchyma and
the main portal vein was obtained with results similar to
that of the standard triphasic MDCT protocol. In
addition, optimal patients’ body-weight-tailored dose of
first bolus of contrast medium for the liver has been deter-
mined based on a definition of the dose which can give
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crease from unenhanced baseline HU of the liver) during
hepatic parenchymal phase [22,23]. The second bolus of
60mL fixed of contrast medium at a 3.5mL/second flow
rate ensured an adequate HAP demonstrating the hyper-
vascularity of the FNH and hypodensity of the central scar
and its maximum peak of enhancement on DP.
In our experience, the split-bolus MDCT protocol
resulted in a reduction in the radiation dose with respect
to the standard triphasic MDCT protocol (respectively
22.78mSv versus 38.87mSv; reduction in dose of approxi-
mately 40%), without compromising image quality. In
addition the new protocol reduces the number of data sets
(637 images for split-bolus versus 878 images for tripha-
sic technique; reduction in the images of 27.5%). Instead
of obtaining two scans separately at the HAP and PVP
during hepatic enhancement, we obtained a single
combined-phase scan.
The unenhanced and DP phases were performed with
both the triphasic and split-bolus MDCT technique for
an adequate comparison between the two techniques
and to demonstrate the effectiveness of split-bolus
MDCT in characterization of the lesion.
Conclusions
In conclusion, this original case demonstrates the high
accuracy of split-bolus MDCT technique in the diagnosis
of FNH in a patient with a tumor. The split-bolus MDCT
technique confirmed the typical features of FNH as did
the triphasic MDCT technique but with a reduction in
radiation dose (approximately 40%) to the patient and
data stored.
The split-bolus MDCT technique can be performed in
the follow-up of patients with known hepatic benign neo-
plasm and more research with large series is necessary in
order to confirm it.
Split-bolus MDCT was able to show the same appearance
of the lesion as the triphasic MDCT technique.
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